GILEAD SCIENCES INC (GIS.DE) Stock Price, Quote, News and Overview
FRA:GIS - Deutsche Boerse Ag - US3755581036 - Common Stock - Currency: EUR
GIS.DE Quote, Performance and Key Statistics
FRA:GIS (3/7/2025, 7:00:00 PM)
107.92
+1.1 (+1.03%)
The current stock price of GIS.DE is 107.92 EUR. In the past month the price increased by 14.37%. In the past year, price increased by 57.92%.
GIS.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
| 1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
| AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
| 1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
| ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
| IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
| 1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 13.19B | ||
| 1MRNA.MI | MODERNA INC | N/A | 12.34B |
Related stock screener links
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 18000
Company Website: https://www.gilead.com/
Investor Relations: https://investors.gilead.com/
Phone: 16505743000
GILEAD SCIENCES INC / GIS.DE FAQ
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of GIS.DE is 107.92 EUR. The price increased by 1.03% in the last trading session.
What is the ticker symbol for GILEAD SCIENCES INC stock?
The exchange symbol of GILEAD SCIENCES INC is GIS and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is GIS.DE stock listed?
GIS.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for GILEAD SCIENCES INC stock?
37 analysts have analysed GIS.DE and the average price target is 104.05 EUR. This implies a price decrease of -3.59% is expected in the next year compared to the current price of 107.92. Check the GILEAD SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GILEAD SCIENCES INC worth?
GILEAD SCIENCES INC (GIS.DE) has a market capitalization of 134.40B EUR. This makes GIS.DE a Large Cap stock.
How many employees does GILEAD SCIENCES INC have?
GILEAD SCIENCES INC (GIS.DE) currently has 18000 employees.
What are the support and resistance levels for GILEAD SCIENCES INC (GIS.DE) stock?
GILEAD SCIENCES INC (GIS.DE) has a support level at 97.14. Check the full technical report for a detailed analysis of GIS.DE support and resistance levels.
Is GILEAD SCIENCES INC (GIS.DE) expected to grow?
The Revenue of GILEAD SCIENCES INC (GIS.DE) is expected to grow by 1.31% in the next year. Check the estimates tab for more information on the GIS.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GILEAD SCIENCES INC (GIS.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GIS.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GIS.DE, evaluating the profitability, health, valuation and growth aspects
- GILEAD SCIENCES INC (GIS.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GILEAD SCIENCES INC (GIS.DE) Sales and EPS estimates to see what analysts future expectations are.
- GILEAD SCIENCES INC (GIS.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GILEAD SCIENCES INC (GIS.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- GILEAD SCIENCES INC (GIS.DE) Stock Chart to make your own analysis
- GILEAD SCIENCES INC (GIS.DE) Latest news and press-releases to stay up to date.
Does GILEAD SCIENCES INC (GIS.DE) stock pay dividends?
GILEAD SCIENCES INC (GIS.DE) has a dividend yield of 2.72%. The yearly dividend amount is currently 2.9. Check the full fundamental report for a detailed analysis of GIS.DE dividend history, reliability and sustainability.
When does GILEAD SCIENCES INC (GIS.DE) report earnings?
GILEAD SCIENCES INC (GIS.DE) will report earnings on 2025-04-23, after the market close.
What is the Price/Earnings (PE) ratio of GILEAD SCIENCES INC (GIS.DE)?
The PE ratio for GILEAD SCIENCES INC (GIS.DE) is 25.39. This is based on the reported non-GAAP earnings per share of 4.25 and the current share price of 107.92 EUR. Check the full fundamental report for a full analysis of the valuation metrics for GIS.DE.
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE is one of the better performing stocks in the market, outperforming 97.05% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE. While GIS.DE has a great profitability rating, there are some minor concerns on its financial health.
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 4.25. The EPS decreased by -34.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.67% | ||
| ROA | 0.81% | ||
| ROE | 2.48% | ||
| Debt/Equity | 1.29 |
GIS.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to GIS.DE. The Buy consensus is the average rating of analysts ratings from 37 analysts.
For the next year, analysts expect an EPS growth of 75.31% and a revenue growth 1.31% for GIS.DE